TGR-63

TGR-63 is a patent-pending small molecule drug candidate developed by IGC Pharma for the treatment of Alzheimer’s disease. It is designed to disrupt the aggregation and structure of amyloid-beta (Aβ) plaques, which are pathological hallmarks of Alzheimer’s disease and contribute to cognitive decline and memory loss. Mechanistically, TGR-63 acts by interfering with intermolecular interactions among Aβ peptides, destabilizing their assembly, and preventing the formation of large toxic aggregates—particularly targeting Aβ42 species associated with neuronal toxicity. Preclinical studies in cell lines and genetically modified mouse models have demonstrated that TGR-63 significantly reduces amyloid plaque burden in critical brain regions such as the cortex (by 78%) and hippocampus (by 85%), improves spatial memory function, enhances long-term potentiation, increases neuronal viability under Aβ42 exposure, shows robust blood-brain barrier penetration (LogP=0.1), and exhibits an excellent safety profile over extended dosing periods without observed toxicity or adverse effects[1][2][3][5][6][8]. As of mid-2025, it remains in preclinical development with plans for Phase 1 clinical trials.